This study will look at the effects of lemborexant on Alzheimer's disease biomarkers found in the cerebrospinal fluid (CSF) and blood in individuals who are poor sleepers
This study will determine the acute effect of lemborexant on CNS tau phosphorylation and other Alzheimer's disease biomarkers in individuals with poor sleep quality.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Lemborexant 25mg will be taken nightly for two consecutive nights.
Placebo will be taken nightly for two consecutive nights
Washington University School of Medicine
St Louis, Missouri, United States
Change in CNS tau phosphorylation
Changes in CSF pT181/T181 ratio compared to placebo
Time frame: 48 hours
Changes in other CSF AD biomarkers
Changes in CSF pS202/S202, pT217/T217, and amyloid-beta
Time frame: 48 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.